Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting period ending November 28, 2025. The report serves to distribute a press release dated November 28, 2025, to U.S. investors pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The provided filing text contains only the cover page and exhibit index for the Form 6-K. It does not include the full text of the press release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other key financial metrics.
Material Changes
As the specific content of the press release (Exhibit 99.1) is not included in the input text, no material changes versus the prior comparable period can be identified from this document alone.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details regarding unusual items. These elements would be contained within the referenced press release, which is not provided in the source text.
Investor Verification Checklist
- Verify the full content of the press release dated November 28, 2025, referenced as Exhibit 99.1.
- Confirm whether the press release contains updated clinical trial data, regulatory milestones, or financial results.
- Check for any new risk factors or forward-looking statements disclosed in the full press release.